These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34971714)

  • 1. How many lives do COVID vaccines save? Evidence from Israel.
    Arbel R; Moore CM; Sergienko R; Pliskin J
    Am J Infect Control; 2022 Mar; 50(3):258-261. PubMed ID: 34971714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
    Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel.
    Saciuk Y; Kertes J; Mandel M; Hemo B; Shamir Stein N; Ekka Zohar A
    Prev Med; 2022 Feb; 155():106947. PubMed ID: 34974072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
    Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
    BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
    Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L
    Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
    Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
    JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Israel's rapid rollout of vaccinations for COVID-19.
    Rosen B; Waitzberg R; Israeli A
    Isr J Health Policy Res; 2021 Jan; 10(1):6. PubMed ID: 33499905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study.
    Agrawal U; Katikireddi SV; McCowan C; Mulholland RH; Azcoaga-Lorenzo A; Amele S; Fagbamigbe AF; Vasileiou E; Grange Z; Shi T; Kerr S; Moore E; Murray JLK; Shah SA; Ritchie L; O'Reilly D; Stock SJ; Beggs J; Chuter A; Torabi F; Akbari A; Bedston S; McMenamin J; Wood R; Tang RSM; de Lusignan S; Hobbs FDR; Woolhouse M; Simpson CR; Robertson C; Sheikh A
    Lancet Respir Med; 2021 Dec; 9(12):1439-1449. PubMed ID: 34599903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.
    Bar-On YM; Goldberg Y; Mandel M; Bodenheimer O; Freedman L; Kalkstein N; Mizrahi B; Alroy-Preis S; Ash N; Milo R; Huppert A
    N Engl J Med; 2021 Oct; 385(15):1393-1400. PubMed ID: 34525275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Waning Immunity after the BNT162b2 Vaccine in Israel.
    Goldberg Y; Mandel M; Bar-On YM; Bodenheimer O; Freedman L; Haas EJ; Milo R; Alroy-Preis S; Ash N; Huppert A
    N Engl J Med; 2021 Dec; 385(24):e85. PubMed ID: 34706170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States.
    Di Fusco M; Marczell K; Deger KA; Moran MM; Wiemken TL; Cane A; de Boisvilliers S; Yang J; Vaghela S; Roiz J
    J Med Econ; 2022; 25(1):605-617. PubMed ID: 35574613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021.
    Steele MK; Couture A; Reed C; Iuliano D; Whitaker M; Fast H; Hall AJ; MacNeil A; Cadwell B; Marks KJ; Silk BJ
    JAMA Netw Open; 2022 Jul; 5(7):e2220385. PubMed ID: 35793085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021.
    Muhsen K; Maimon N; Mizrahi AY; Varticovschi B; Bodenheimer O; Cohen D; Dagan R
    JAMA Netw Open; 2022 Jul; 5(7):e2219940. PubMed ID: 35796153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 Vaccine Effectiveness and Digital Pandemic Surveillance in Germany (eCOV Study): Web Application-Based Prospective Observational Cohort Study.
    Lang AL; Hohmuth N; Višković V; Konigorski S; Scholz S; Balzer F; Remschmidt C; Leistner R
    J Med Internet Res; 2024 Jun; 26():e47070. PubMed ID: 38833299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia.
    Batmunkh B; Otgonbayar D; Shaarii S; Khaidav N; Shagdarsuren OE; Boldbaatar G; Danzan NE; Dashtseren M; Unurjargal T; Dashtseren I; Dagvasumberel M; Jagdagsuren D; Bayandorj O; Biziya B; Surenjid S; Togoo K; Bat-Erdene A; Narmandakh Z; Choijilsuren G; Batmunkh U; Soodoi C; Boldbaatar EA; Byambatsogt G; Byambaa O; Deleg Z; Enebish G; Chuluunbaatar B; Zulmunkh G; Tsolmon B; Gunchin B; Chimeddorj B; Dambadarjaa D; Sandag T
    PLoS One; 2023; 18(12):e0295167. PubMed ID: 38064430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
    Sacco C; Del Manso M; Mateo-Urdiales A; Rota MC; Petrone D; Riccardo F; Bella A; Siddu A; Battilomo S; Proietti V; Popoli P; Menniti Ippolito F; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M;
    Lancet; 2022 Jul; 400(10346):97-103. PubMed ID: 35780801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.